EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”.
EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium.
Shortlisted are:
Autifony (London, UK): A healthcare biotech based at Imperial College London, focused on the development of high value novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.
Bio-on (Bologna, Italy): Bio-on works in industrial biotechnology applied to widely used materials, creating natural products and solutions based on renewable resources or on agricultural processing waste material.
Biosyntia (Horshølm, Denmark): An industrial biotech SME, providing unique fermentation solutions to chemical manufacturing companies.
Erytech Pharma (Lyon, France): A biopharmaceutical company developing an innovative concept to starve cancer cells in specific essential nutrients, and quickly induce their death without impairing any healthy cells.
to-BBB (Leiden, The Netherlanda): A biotech developing novel treatments for patients with devastating brain diseases. Its lead clinical programs target multiple types of brain cancers, including brain metastases from breast cancer, as well as neuro-inflammatory diseases.
This year’s award ceremony reportedly has a focus on financing, with the European Investment Bank presenting its Growth Financing Facility for funding innovative companies in the EU, and the European Commission illustrating its SME Instrument under Horizon 2020.
Click here for further information.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.